相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rodent models of cholestatic liver disease: A practical guide for translational research
Eva Gijbels et al.
LIVER INTERNATIONAL (2021)
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
Marcos Pedrosa et al.
CONTEMPORARY CLINICAL TRIALS (2020)
Microbial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis
Xinyang Song et al.
NATURE (2020)
Global chemical effects of the microbiome include new bile-acid conjugations
Robert A. Quinn et al.
NATURE (2020)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
Michael K. Badman et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction
Ping An et al.
LIVER INTERNATIONAL (2020)
CYP7A1 expression in hepatocytes is retained with upregulated fibroblast growth factor 19 in pediatric biliary atresia
Yasuhiro Hasegawa et al.
HEPATOLOGY RESEARCH (2019)
Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics
Amy G. Feldman et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Obeticholic acid may increase the risk of gallstone formation in susceptible patients
Samer Al-Dury et al.
JOURNAL OF HEPATOLOGY (2019)
FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis
Marcel Sorribas et al.
JOURNAL OF HEPATOLOGY (2019)
Bile acid metabolites control TH17 and Treg cell differentiation
Saiyu Hang et al.
NATURE (2019)
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents
Eloy D. Hernandez et al.
HEPATOLOGY COMMUNICATIONS (2019)
Comparative analysis on liver transcriptome profiles of different methods to establish type 2 diabetes mellitus models in Guangxi Bama mini-pig
Yanjun Wu et al.
GENE (2018)
Biliary Atresia: Clinical and Research Challenges for the Twenty-First Century
Jorge A. Bezerra et al.
HEPATOLOGY (2018)
Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives
Juan P. Arab et al.
HEPATOLOGY (2017)
Biliary Atresia: Indications and Timing of Liver Transplantation and Optimization of Pretransplant Care
Shikha S. Sundaram et al.
LIVER TRANSPLANTATION (2017)
Bile duct ligature in young rats: A revisited animal model for biliary atresia
Matias Garrido et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2017)
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis
Peter Fickert et al.
JOURNAL OF HEPATOLOGY (2017)
The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
Philipp Schwabl et al.
JOURNAL OF HEPATOLOGY (2017)
Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
David C. Tully et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
A single-cell survey of the small intestinal epithelium
Adam L. Haber et al.
NATURE (2017)
Bile acids initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory response
Shi-Ying Cai et al.
JCI INSIGHT (2017)
Nuclear receptors and nonalcoholic fatty liver diseases
Matthew C. Cave et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2016)
Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats
Maria Ubeda et al.
JOURNAL OF HEPATOLOGY (2016)
The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats
Len Verbeke et al.
AMERICAN JOURNAL OF PATHOLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
The Interplay of the Gut Microbiome, Bile Acids, and Volatile Organic Compounds
Nidhi M. Sagar et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2015)
Bile acids and the gut microbiome
Jason M. Ridlon et al.
CURRENT OPINION IN GASTROENTEROLOGY (2014)
Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats
Len Verbeke et al.
HEPATOLOGY (2014)
Bile acid transporters and regulatory nuclear receptors in the liver and beyond
Emina Halilbasic et al.
JOURNAL OF HEPATOLOGY (2013)
Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis
Salvatore Modica et al.
GASTROENTEROLOGY (2012)
Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice
Bo Kong et al.
HEPATOLOGY (2012)
Hydroxysteroid dehydrogenases (HSDs) in bacteria - A bioinformatic perspective
Michael Kisiela et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2012)
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Anna C. Calkin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Effects of Age and Region on Fecal Microflora in Elderly Subjects Living in Bama, Guangxi, China
Liang Zhao et al.
CURRENT MICROBIOLOGY (2011)
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
Raffaella M. Gadaleta et al.
GUT (2011)
Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray
Hiroyuki Higashiyama et al.
ACTA HISTOCHEMICA (2008)
Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations
Gernot Zollner et al.
MOLECULAR PHARMACEUTICS (2006)
Bile salt biotransformations by human intestinal bacteria
JM Ridlon et al.
JOURNAL OF LIPID RESEARCH (2006)
FXR regulates organic solute transporters alpha and beta in the adrenal gland, kidney, and intestine
H Lee et al.
JOURNAL OF LIPID RESEARCH (2006)
NO-1886 upregulates ATP binding cassette transporter A1 and inhibits diet-induced atherosclerosis in Chinese Bama minipigs
Chi Zhang et al.
JOURNAL OF LIPID RESEARCH (2006)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation
YQ Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
CJ Sinal et al.
CELL (2000)
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
B Goodwin et al.
MOLECULAR CELL (2000)
分享论文
